Amniotic membrane was applied to a series of chronic wounds referred to a formal wound clinic for aggressive management, after prior, traditional treatment methods were found ineffective, over a period of 1 month. In each case, failure of traditional therapy was followed by placement of a dehydrated amniotic membrane allograft and the healing time course was documented with charted measurements. Wounds treated with the amniotic membrane allograft demonstrated improved healing, with a change in the healing trajectory from that previously noted. Dehydrated human amniotic membrane represents a potentially effective addition to existing wound care therapies, with further formal clinical studies indicated. amniotic membrane; chronic wounds; allograft B oth the primary cause and the under lying aetiology of wound persistence can be numerous and diverse. Primary pathological conditions underlying chronic wounds include diabetic neu rovascular ulcers, chronic venous insufficiency, microvascular arterial disease, posttraumatic wounds and postoperative wound dehiscence. The underlying aetiologies for the development of chro nicity can involve a number of mechanisms, includ ing underlying infection, vascular insufficiency, unbalanced wound healing biomolecular micro environments, and other factors. Recognition of the specific conditions and underly ing predisposing factors for chronicity have led to the recent creation of comprehensive, evidencebased guidelines for wound care, as well as formal wound centres.
2,3 The development of evidencebased guide lines has improved the general approach to care of nonhealing wounds, and has made new information available to the larger clinician population.
3-11
Multidisciplinary algorithms for addressing chron ic wounds have been advanced and are available from a number of sources. 2, 3, [12] [13] [14] inability of a wound to heal by at least 50%, after being treated for a period of 1 month, 16,17 a definition used by Medicare (US national social insurance pro gramme) to define an endpoint needed to permit a move to more expensive biological therapies.
The relatively recent development of synthetic skin substitutes, natural allografts and xenografts has presented new hope in clinicians' efforts to close refractory ulcers. The general issues with rising medical costs have been of particular interest, given the economic significance of nonhealing wounds in the patient populations under consideration. [18] [19] [20] [21] [22] Human amniotic membrane has been described in peerreviewed literature as a wound care treatment for over 100 years. Davis reported a series of 550 cases using skin transplantation, as early as 1910. 23 John conducted a review of the use of amniotic membrane in wounds, treating ulcers, burns and other dermal injuries, as well as applications in plastic and recon structive surgery at other sites. 24 The widespread use of the material, however, was limited due to a variety of obvious logistic problems, including inconsistent presentation of material, difficulty processing placen tas into amniotic membrane treatments, and diffi culty in handling and surgical use, sterilisation, transportation, and storage. 3, 8, 25, 26 Over the past several years, a dehydrated version of human amniotic membrane has been prepared and developed for use as a wound therapy. Currently used for over 6 years in eye surgery, some 45 000 cases have occurred using the material for pterygium repair, burns and conjunctival reconstruction surgery, even in children (internal product information, MiMedx Group, Inc.). From an analysis of both manufacturer's information and the medical literature, there are vir tually no significant medical complications or side effects reported from the use of the material.
27
In particular, the use of dehydrated human amni otic membrane has been explored as a costeffective approach to facilitating chronic wound closure in our practice, and we believe the material could be competitive with alternative strategies in both price and outcome. 28 In preliminary case studies, similar to those described here, the material seemed to work quickly to improve cost to closure, and it is compara bly priced to competing biological products. The material does not require special handling or storage precautions. It is pliable at room temperature, and has a shelf life of up to 5 years. In its current com mercial configuration, it comes in a number of sizes, which permits the use of smaller pieces as a wound heals if multiple pieces are required, reducing waste. Finally, because fewer applications are necessary, this reduces total treatment costs to the patient, includ ing the total amount of copay and deductible amounts patients must pay.
This clinical series was undertaken to document the use and effectiveness of dehydrated human amniotic membrane (dHAM) allografts as a viable biologic treatment in nonhealing wounds. Used historically on many wound types in the natural form, as noted above, human amniotic membrane has gained wide use in ophthalmic wounds and sur gery. The material was used here to confirm the applicability of dHAM in cutaneous wounds as well.
Methods
A retrospective series of five representative patients were selected from a larger group of 12 patients pre senting to an advanced stateoftheart wound clinic (Diversified Clinical Services, Inc.), between May and September 2011. Patients treated had received dehydrated human amniotic membrane allografts after failing initial traditional therapies using con servative algorithms.
15
Adult patients, over 18 years old, with nonheal ing wounds were offered the commercially available dHAM allograft (EpiFix; MiMedx Group, Inc.), after failing to heal by at least 50% after at least 1 month of traditional therapy.
Participating chronic wound patients were selected from those receiving the allografts, who were repre sentative of a diverse range of underlying aetiologies to demonstrate the applicability and effectiveness of dHAM allografts. Initial therapy of all patients included traditional care using evidencebased proto cols of the Diversified Clinical Services group, 15 and documented failure of traditional therapy after 1 month of usual care, using the criteria stated above.
The retrospective patient selection ultimately resulted in patients being treated with the following underlying pathologies: l Venous leg ulcers l Crush injury l Arterial insufficiency l Immunologic skin disease/scleroderma l Snake bite. All patients had appropriately signed release forms, as standard procedure, as part of their treatment in the wound clinic.
The dHAM allografts were applied according to the manufacturer's specifications and approach.
The wound bed was prepared using sharp debride ment, to provide a viable wound base prior to graft implantation and the wound was examined to be free from clinical signs of infection.
Graft selection was undertaken to fit an appropri atesized graft and minimise waste of the material. The graft was cut using sterile dry scissors to fit within the wound margin or provide minimal onlay overlap. Graft orientation, with epithelial layer fac ing up, was confirmed by noting the embossed let tering on the material.
The primary dressing included a nonadherent contact layer created by a commercially available nonadherent dressing (either Adaptic Touch [Systa genix] or Mepital [Mölnlycke]) and was not dis turbed for at least 2 weeks. A secondary dressing, using a moist saline gauze dressing, was applied to provide a moist wound healing environment.
Other support therapies were permitted including offloading, compression, and decompression thera pies. Patients were typically treated with only one graft, with the option of an additional graft at the clinician's prerogative.
All patients were followedup in clinic by the investigating clinician (JF), typically on a weekly basis. At each followup visit, the wound was photo graphed and direct measurements of the wound area were taken (length×width). The primary end point was wound closure, defined as full epitheliali sation of the wound, assessed both clinically and as documented in the photographs.
Results
l Patient 1 was a 97yearold white female, who presented with venous leg ulcer of > 1 month's dura tion, involving her left calf. The patient had some history of hypertension, though this was not con sidered significant. The patient had experienced no improvement of her underlying lesion after several debridements, aggressive compression and oral antibiotics (trim sulfa). Dehydrated human amni otic membrane was applied in two applications, over a 3month period, with significant improve ment observed in wound closure (Fig 1) . Time to healing from graft placement to wound epitheliali sation was 91 days (Fig 2) .
l Patient 2 was a 31yearold, otherwise healthy, white female who sustained a crush injury to her left calf and developed a chronic wound (Fig 3) . The patient developed seroma necrosis that required inpatient surgical debridement. After surgery, patient developed a 2+ pitting lymphoedema below the knee, successfully treated with serial multilayer com pression wraps (Profore; Smith & Nephew). At the time of EpiFix application, oedema was well control led and managed with a twolayer compression stocking (Tubigrip; Mölnlycke) at 20mm/Hg. dHAM was applied after surgery and the patient healed com pletely with significant epithelialisation and mini mal scarring. Time to healing from graft placement to wound epithelialisation was 39 days (Fig 4) .
l Patient 3 was a 60yearold, nonsmoking white male with chronic arterial insufficiency of the right ankle, of 3 weeks' duration on presentation. The patient's wound initially showed no improvement after revascularisation surgery (Fig 5) . The patient was treated with dHAM therapy and the wound closed within 1 month of application, leaving no scar tissue behind. Time to healing from graft placement to wound epithelialisation was 16 days (Fig 6) .
l Patient 4 was a 56yearold black female with scle roderma and venous leg ulcers who had not responded to therapy, including aggressive debride ment, antibiotics and dressing changes over a 4year period (Fig 7) . Therapy also included oral and topi cal antiinflammatories (prednisone dosepak, kena log cream 0.01%). Of two initial wounds, one was noted to be healed completely within 1 month, after one application of dHAM. The second wound showed 30% improvement over a 1month period. Time to healing from graft placement to wound epithelialisation was 154 days (Fig 8) .
l Patient 5 was a 49yearold white female, who sustained a snake bite and pit viper envenomation to the left posterior heel, with subsequent develop ment of cellulitis requiring hospitalisation, intra venous antibiotics (vancomycin IV), dressing changes (Biostep Ag; Smith & Nephew), surgical sharp debridement and oral antibiotics (Bactrim DS). After 4 weeks of unsuccessful use of traditional methods, dHAM was applied to the wound area. The site was noted to heal within 2 weeks of initial application (Fig 9) . Of interest, there was essent ially no improvement in depth of the wound, and even some regression with the development of necrotic subcutaneous tissue requiring debride ment, following standard protocol, prior to the application of the allograft. Time to healing from graft placement to wound epithelialisation was 26 days (Fig 10) .
Discussion
The recent development of a stabilised form of dHAM, through proprietary processing methods, has resulted in a clinical wound allograft that has demonstrated effectiveness in healing wounds, burns and reconstructive surgery in the eye.
Each of the cases discussed were presented to a formal wound clinic for care and were found to have a nonhealing wound. Patient history and physical findings suggested that these wounds would not further respond to standard conservative measures and would benefit from a more advanced biological therapy. Patients were treated with debri dement, application of dHAM, according to manu facturer's recommendations, and followed to com pletion. No adverse effects were noted, in keeping with the historically noted safety of the allografts.
Human amniotic membrane exhibits a number of unique properties, including: 35, 36 l Is capable of reducing pain at the treatment site.
37,38
Each of the patients in this case series were repre sentative examples of the type of referrals to a chronic wound clinic. Each was treated with dehy drated human amniotic membrane after failure of traditional methods and advanced therapies.
Conclusion
This study presents a series of cases for whom tradi tional wound therapy treatment was unsuccessful and where treatment with advanced biologic grafts was recommended. Recently expanded to include the treatment of other wounds, amniotic membrane shows promise in treating chronic wounds unre sponsive to traditional therapies even within a for mal wound clinic environment directed by evidence based treatment algorithm guidelines.
Patients treated responded over several weeks from application where a nonhealing wound was observed. As an advanced biologic therapy, applica tion of an amniotic membrane allograft is not indi cated for the routine treatment of wounds. Similar to other advanced biologic treatments, it is indicat ed for those wounds that demonstrate a pattern of resolution that indicates where a nonhealing wound environment is present. Further investiga tion with this material in formal clinical trials is clearly warranted to confirm the costeffective nature of this therapy. n 
